ELSEVIER

Diabetes Research and Clinical Practice 39 (1998) 229–231

DIABETES RESEARCH AND CLINICAL PRACTICE

Author index of volume 39

Abuaisha, B.B., J.B. Costanzi, A.J. Boulton, Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: a long-term study **39**, 115
Abuaisha, B., S. Kumar, R. Malik, A.J. Boulton, Relationship of elevated urinary albumin excretion to components of the metabolic syndrome in non-insulin-dependent diabetes mellitus **39**, 93
Abu Sayeed, M., A. Banu, M.A. Malek, A.K. Azad Khan, Blood pressure and coronary heart disease in NIDDM subjects at diagnosis: prevalence and risks in a Bangladeshi population **39**, 147
Agardh, C.-D., see Lövestam-Adrian, M. **39**, 11
Agardh, E., see Lövestam-Adrian, M. **39**, 11
Araujo-Vilar, D., C.A. Rega-Liste, D.A. Garcia-Estevez, F. Sarmiento-Escalona, V. Mosquera-Tallon, J. Cabezas-Cerrato, Minimal model of glucose metabolism: Modified equations and its application in the study of insulin sensitivity in obese subjects **39**, 129
Araújo-Vilar, D., see García-Estévez, D.A. **39**, 107
Azad Khan, A.K., see Abu Sayeed, M. **39**, 147

Babazono, T., see Miura, J. **39**, 31
Bandoh, T., see Ishikawa, J. **39**, 3
Banu, A., see Abu Sayeed, M. **39**, 147
Boixeda, D., see de Luis, D.A. **39**, 143
Borgeld, H.-J., see Miura, J. **39**, 31
Boulton, A.J., see Abuaisha, B. **39**, 93
Boulton, A.J., see Abuaisha, B.B. **39**, 115
Boulton, A.J., see Shaw, J.E. **39**, 55
Bursey, D.L., see Feinglos, M.N. **39**, 193

Cabezas-Cerrato, J., see Araujo-Vilar, D. **39**, 129
Cabezas-Cerrato, J., see García-Estévez, D.A. **39**, 107
Califano, L., see Romano, G. **39**, 101
Campillo, J.E., see Serraclara, A. **39**, 19
Canton, R., see de Luis, D.A. **39**, 143
Carlsen, S.M., V. Grill, I. Følling, Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease **39**, 47
Contiero, E., R. Ferrari, G.M. Vaselli, M. Folin, Quantification of apolipoprotein AI-containing lipoprotein particles in non-insulin-dependent diabetes mellitus **39**, 201
Costanzi, J.B., see Abuaisha, B.B. **39**, 115
Cucinotta, D., see Romano, G. **39**, 101
Cuisinier-Raynal, J.C., see Papoz, L. **39**, 219

Darrack, R., see Papoz, L. **39**, 219
Deary, I.J., see Perros, P. **39**, 23
DeAtkine, D.D., see Feinglos, M.N. **39**, 193
de la Calle, H., see de Luis, D.A. **39**, 143
Delcourt, C., see Papoz, L. **39**, 219
de Luis, D.A., H. de la Calle, G. Roy, C. Martin de Argila, S. Valdezate, R. Canton, D. Boixeda, *Helicobacter pylori* infection and insulin-dependent diabetes mellitus **39**, 143
Di Benedetto, A., see Romano, G. **39**, 101
Di Cesare, E., see Romano, G. **39**, 101
Domínguez, E., see Serraclara, A. **39**, 19

Eibl, N., C. Schnack, M. Frank, G. Schernthaner, Initial urinary albumin excretion determines the progression of microalbuminuria in patients with type-2 diabetes and normotensive blood pressure values despite improved metabolic control **39**, 39
English, J.S., see Feinglos, M.N. **39**, 193
Engström, L., see Lundman, B. **39**, 157

Feinglos, M.N., C.R. Thacker, B. Lobaugh, D.D. DeAtkine, D.B. McNeill, J.S. English, D.L. Bursey, Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus **39**, 193
Ferrari, R., see Contiero, E. **39**, 201
Følling, I., see Carlsen, S.M. **39**, 47
Folin, M., see Contiero, E. **39**, 201
Frank, M., see Eibl, N. **39**, 39
Frier, B.M., see Perros, P. **39**, 23
Fujito, T., see Miura, J. **39**, 31
Fukushima, N., see Yamada, H. **39**, 211

0168-8227/97/$19.00 © 1998 Elsevier Science Ireland Ltd. All rights reserved.
PII S0168-8227(97)00113-7

García-Estévez, D.A., D. Araújo-Vilar, J. Cabezas-Cerrato, Non-insulin-mediated glucose uptake in several insulin-resistant states in the postabsortive period **39**, 107
Garcia-Estevez, D.A., see Araujo-Vilar, D. **39**, 129
Giofrè, C., see Romano, G. **39**, 101
Gokal, R., see Shaw, J.E. **39**, 55
Grasso, G., see Lunetta, M. **39**, 165
Grill, V., see Carlsen, S.M. **39**, 47

Hawkins, F., see Serraclara, A. **39**, 19
Hayashi, S., see Ishikawa, J. **39**, 3
Hellström, S., see Kniola, B. **39**, 173
Hiltunen, L., E. Läärä, S.-L. Kivelä, S. Keinänen-Kiukaanniemi, Glucose tolerance and mortality in an elderly Finnish population **39**, 75
Hollis, S., see Shaw, J.E. **39**, 55

Ip, T.-P., see Wang, W.-Q. **39**, 185
Ishikawa, J., H. Mitani, T. Bandoh, M. Kimura, T. Totsuka, S. Hayashi, Hypoglycemic and hypotensive effects of 6-cyclohexyl-2′-*O*-methyl-adenosine, an adenosine A_1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia **39**, 3
Iwamoto, Y., see Miura, J. **39**, 31
Iwamoto, Y., see Yamada, H. **39**, 211

Jayaraman, M., see Viswanathan, V. **39**, 63

Kasahara, T., see Yamada, H. **39**, 211
Kawasaki, E., see Yamada, H. **39**, 211
Keinänen-Kiukaanniemi, S., see Hiltunen, L. **39**, 75
Kimura, M., see Ishikawa, J. **39**, 3
Kivelä, S.-L., see Hiltunen, L. **39**, 75
Kniola, B., S. Hellström, J. Ludvigsson, Islet cell surface antibodies (ICSA) do bind to human pancreas: computerised, quantitative determination of ICSA using both pre- and postembedding immunocolloidal techniques **39**, 173
Koike, A., see Yamada, H. **39**, 211
Kubo, H., see Yamada, H. **39**, 211
Kumar, S., see Abuaisha, B. **39**, 93

Läärä, E., see Hiltunen, L. **39**, 75
Lam, K.S., see Wang, W.-Q. **39**, 185
Le Moli, R., see Lunetta, M. **39**, 165
Lobaugh, B., see Feinglos, M.N. **39**, 193
Lokrou, A., see Papoz, L. **39**, 219
Lövestam-Adrian, M., E. Agardh, C.-D. Agardh, The incidence of nephropathy in type 1 diabetic patients with proliferative retinopathy: a 10-year follow-up study **39**, 11
Ludvigsson, J., see Kniola, B. **39**, 173
Lundman, B., L. Engström, Diabetes and it's complications in a Swedish county **39**, 157
Lunetta, M., R. Le Moli, G. Grasso, L. Sangiorgio, A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy **39**, 165

Malek, M.A., see Abu Sayeed, M. **39**, 147
Malik, R., see Abuaisha, B. **39**, 93
Martin de Argila, C., see de Luis, D.A. **39**, 143
Mathai, T., see Viswanathan, V. **39**, 63
Matsunaga, R., see Miura, J. **39**, 31
Matsuura, N., see Yamada, H. **39**, 211
McNeill, D.B., see Feinglos, M.N. **39**, 193
Mitani, H., see Ishikawa, J. **39**, 3
Miura, J., see Yamada, H. **39**, 211
Miura, J., Y. Uchigata, A. Sato, R. Matsunaga, T. Fujito, H.-J. Borgeld, M. Tanaka, T. Babazono, C. Takahashi, Y. Iwamoto, An IDDM patient who complained of chest oppression with ischemic changes on ECG in insulin-induced hypoglycemia **39**, 31
Mizota, M., see Yamada, H. **39**, 211
Moretti, G., see Romano, G. **39**, 101
Mosquera-Tallon, V., see Araujo-Vilar, D. **39**, 129
Mutoh, K., see Yamada, H. **39**, 211

Nagataki, S., see Yamada, H. **39**, 211

Omori, Y., see Yamada, H. **39**, 211
Otani, T., see Yamada, H. **39**, 211

Papoz, L., C. Delcourt, A. Ponton-Sanchez, A. Lokrou, R. Darrack, I.A. Touré, J.C. Cuisinier-Raynal, Clinical classification of diabetes in tropical West Africa **39**, 219
Payne, C.B., R.S. Scott, Hospital discharges for diabetic foot disease in New Zealand: 1980–1993 **39**, 69
Pérez, C., see Serraclara, A. **39**, 19
Perros, P., I.J. Deary, B.M. Frier, Factors influencing preference of insulin regimen in people with type 1 (insulin–dependent) diabetes **39**, 23
Ponton-Sanchez, A., see Papoz, L. **39**, 219

Rajbhandari, S.M., R.M. Wilson, Unusual infections in diabetes **39**, 123
Ramachandran, A., see Viswanathan, V. **39**, 63
Rega-Liste, C.A., see Araujo-Vilar, D. **39**, 129
Romano, G., G. Moretti, A. Di Benedetto, C. Giofrè, E. Di Cesare, G. Russo, L. Califano, D. Cucinotta, Skin lesions in diabetes mellitus: prevalence and clinical correlations **39**, 101
Roy, G., see de Luis, D.A. **39**, 143
Russo, G., see Romano, G. **39**, 101

Sangiorgio, L., see Lunetta, M. **39**, 165
Sarmiento-Escalona, F., see Araujo-Vilar, D. **39**, 129
Sato, A., see Miura, J. **39**, 31
Sato, A., see Yamada, H. **39**, 211
Schernthaner, G., see Eibl, N. **39**, 39
Schnack, C., see Eibl, N. **39**, 39
Scott, R.S., see Payne, C.B. **39**, 69
Serraclara, A., F. Hawkins, C. Pérez, E. Domínguez, J.E. Campillo, M.D. Torres, Hypoglycemic action of an oral fig-leaf decoction in type-I diabetic patients **39**, 19
Shaw, J.E., R. Gokal, S. Hollis, A.J. Boulton, Does peripheral neuropathy invariably accompany nephropathy in type 1 diabetes mellitus? **39**, 55

Snehalatha, C., see Viswanathan, V. **39**, 63

Takahashi, C., see Miura, J. **39**, 31
Tanaka, M., see Miura, J. **39**, 31
Thacker, C.R., see Feinglos, M.N. **39**, 193
Torres, M.D., see Serraclara, A. **39**, 19
Totsuka, T., see Ishikawa, J. **39**, 3
Touré, I.A., see Papoz, L. **39**, 219

Uchigata, Y., see Miura, J. **39**, 31
Uchigata, Y., see Yamada, H. **39**, 211

Valdezate, S., see de Luis, D.A. **39**, 143
Vaselli, G.M., see Contiero, E. **39**, 201
Viswanathan, V., C. Snehalatha, T. Mathai, M. Jayaraman, A. Ramachandran, Cardio vascular morbidity in proteinuric South Indian NIDDM patients **39**, 63

Wang, W.-Q., T.-P. Ip, K.S. Lam, Changing prevalence of retinopathy in newly diagnosed non-insulin dependent diabetes mellitus patients in Hong Kong **39**, 185
Wilson, R.M., see Rajbhandari, S.M. **39**, 123

Yamada, H., Y. Uchigata, E. Kawasaki, N. Matsuura, T. Otani, A. Sato, K. Mutoh, T. Kasahara, N. Fukushima, A. Koike, M. Mizota, J. Miura, H. Kubo, A. Yamaguchi, S. Nagataki, Y. Omori, Y. Iwamoto, Onset age-dependent variations of three islet specific autoantibodies in Japanese IDDM patients **39**, 211
Yamaguchi, A., see Yamada, H. **39**, 211

ELSEVIER

Diabetes Research and Clinical Practice 39 (1998) 233–236

DIABETES RESEARCH AND CLINICAL PRACTICE

Subject index of volume 39

Acromegaly; Non-insulin mediated glucose uptake; Diabetes mellitus; Obesity; Cushing's disease **39**, 107

Acupuncture; Diabetes mellitus; Painful peripheral neuropathy **39**, 115

Adenosine analogue; Spontaneously hypertensive rat; Hyperglycemia; Glucose; Free fatty acid; Triglyceride **39**, 3

Africa; Diabetes mellitus; Classification; C-peptide; Epidemiology **39**, 219

Aged; Diabetes; Follow-up study; Glucose tolerance; Mortality; Prognosis **39**, 75

Apolipoprotein AI-containing particles; Atherosclerotic risk; Electroimmunoassay; High density lipoprotein subfractions; Non-insulin-dependent diabetes mellitus **39**, 201

Atherosclerotic risk; Apolipoprotein AI-containing particles; Electroimmunoassay; High density lipoprotein subfractions; Non-insulin-dependent diabetes mellitus **39**, 201

Autoantibodies; IDDM; RIA; Colloidal gold; Quantification; Human pancreas **39**, 173

Basal-bolus insulin regimen; Type 1 (insulin–dependent) diabetes mellitus; Insulin; Personality; Treatment satisfaction **39**, 23

Blood pressure; CHD; NIDDM; BMI; WHR; Relative risk **39**, 147

BMI; Blood pressure; CHD; NIDDM; WHR; Relative risk **39**, 147

Cardiovascular disease; Metformin; Insulin resistance; Weight reduction **39**, 47

Cardiovascular morbidity; Proteinuria; NIDDM; Hypertension **39**, 63

CHD; Blood pressure; NIDDM; BMI; WHR; Relative risk **39**, 147

Classification; Diabetes mellitus; C-peptide; Africa; Epidemiology **39**, 219

Colloidal gold; Autoantibodies; IDDM; RIA; Quantification; Human pancreas **39**, 173

C-peptide; Diabetes mellitus; Classification; Africa; Epidemiology **39**, 219

Cushing's disease; Non-insulin mediated glucose uptake; Diabetes mellitus; Obesity; Acromegaly **39**, 107

Diabetes; Aged; Follow-up study; Glucose tolerance; Mortality; Prognosis **39**, 75

Diabetes; *Ficus carica*; Hyperglycemia; Hypoglycemic action **39**, 19

Diabetes mellitus; Acupuncture; Painful peripheral neuropathy **39**, 115

Diabetes mellitus; Classification; C-peptide; Africa; Epidemiology **39**, 219

Diabetes mellitus; Diabetic neuropathy; Diabetic nephropathy; Renal transplantation **39**, 55

Diabetes mellitus; Diabetic neuropathy; Neuropathy screening instrument; Diabetic neuropathy score **39**, 165

Diabetes mellitus; *Helicobacter pylori* seroprevalence; Pathogenesis **39**, 143

Diabetes mellitus; Infection; Malignant otitis externa; Necrotising-fascitis; Psoas abscess; Fournier's gangrene **39**, 123

Diabetes mellitus; Non-insulin mediated glucose uptake; Obesity; Acromegaly; Cushing's disease **39**, 107

0168-8227/97/$19.00 © 1998 Elsevier Science Ireland Ltd. All rights reserved.

PII S0168-8227(97)00114-9

Diabetes mellitus; Skin lesions; IDDM; NIDDM; Metabolic control **39**, 101

Diabetes; Prevalence; Retinopathy; Nephropathy; Loss of pallesthesia macrovascular complications **39**, 157

Diabetic foot; Hospital admissions **39**, 69

Diabetic nephropathy; Diabetic neuropathy; Diabetes mellitus; Renal transplantation **39**, 55

Diabetic neuropathy; Diabetic nephropathy; Diabetes mellitus; Renal transplantation **39**, 55

Diabetic neuropathy; Neuropathy screening instrument; Diabetic neuropathy score; Diabetes mellitus **39**, 165

Diabetic neuropathy score; Diabetic neuropathy; Neuropathy screening instrument; Diabetes mellitus **39**, 165

Electroimmunoassay; Apolipoprotein AI-containing particles; Atherosclerotic risk; High density lipoprotein subfractions; Non-insulin-dependent diabetes mellitus **39**, 201

Elevated urinary albumin excretion rate; Non-insulin-dependent diabetes mellitus; Metabolic syndrome; Ethnic differences **39**, 93

Epidemiology; Diabetes mellitus; Classification; C-peptide; Africa **39**, 219

Ethnic differences; Non-insulin-dependent diabetes mellitus; Elevated urinary albumin excretion rate; Metabolic syndrome **39**, 93

Ficus carica; Diabetes; Hyperglycemia; Hypoglycemic action **39**, 19

Follow-up study; Aged; Diabetes; Glucose tolerance; Mortality; Prognosis **39**, 75

Fournier's gangrene; Diabetes mellitus; Infection; Malignant otitis externa; Necrotising-fascitis; Psoas abscess **39**, 123

Free fatty acid; Adenosine analogue; Spontaneously hypertensive rat; Hyperglycemia; Glucose; Triglyceride **39**, 3

Glucose; Adenosine analogue; Spontaneously hypertensive rat; Hyperglycemia; Free fatty acid; Triglyceride **39**, 3

Glucose effectiveness; Minimal model; Insulin sensitivity; Interstitial insulin; Obesity **39**, 129

Glucose tolerance; Aged; Diabetes; Follow-up study; Mortality; Prognosis **39**, 75

***Helicobacter pylori* seroprevalence**; Diabetes mellitus; Pathogenesis **39**, 143

High density lipoprotein subfractions; Apolipoprotein AI-containing particles; Atherosclerotic risk; Electroimmunoassay; Non-insulin-dependent diabetes mellitus **39**, 201

Hospital admissions; Diabetic foot **39**, 69

Human pancreas; Autoantibodies; IDDM; RIA; Colloidal gold; Quantification **39**, 173

Hyperglycemia; Adenosine analogue; Spontaneously hypertensive rat; Glucose; Free fatty acid; Triglyceride **39**, 3

Hyperglycemia; Diabetes; *Ficus carica*; Hypoglycemic action **39**, 19

Hypertension; Cardiovascular morbidity; Proteinuria; NIDDM **39**, 63

Hypertension; Type-2 diabetes; Metabolic control; Microalbuminuria **39**, 39

Hypoglycemia; Myocardial ischemia; IDDM; Mitochondrial gene **39**, 31

Hypoglycemic action; Diabetes; *Ficus carica*; Hyperglycemia **39**, 19

IDDM; Autoantibodies; RIA; Colloidal gold; Quantification; Human pancreas **39**, 173

IDDM; Hypoglycemia; Myocardial ischemia; Mitochondrial gene **39**, 31

IDDM; Skin lesions; Diabetes mellitus; NIDDM; Metabolic control **39**, 101

Infection; Diabetes mellitus; Malignant otitis externa; Necrotising-fascitis; Psoas abscess; Fournier's gangrene **39**, 123

Insulin resistance; Metformin; Cardiovascular disease; Weight reduction **39**, 47

Insulin sensitivity; Minimal model; Glucose effectiveness; Interstitial insulin; Obesity **39**, 129

Insulin; Type 2 diabetes mellitus; Sulfonylurea **39**, 193

Insulin; Type 1 (insulin–dependent) diabetes mellitus; Personality; Treatment satisfaction; Basal-bolus insulin regimen **39**, 23

Interstitial insulin; Minimal model; Insulin sensitivity; Glucose effectiveness; Obesity **39**, 129

Loss of pallesthesia macrovascular complications; Prevalence; Diabetes; Retinopathy; Nephropathy **39**, 157

Malignant otitis externa; Diabetes mellitus; Infection; Necrotising-fascitis; Psoas abscess; Fournier's gangrene **39**, 123

Metabolic control; Skin lesions; Diabetes mellitus; IDDM; NIDDM **39**, 101

Metabolic control; Type-2 diabetes; Microalbuminuria; Hypertension **39**, 39

Metabolic syndrome; Non-insulin-dependent diabetes mellitus; Elevated urinary albumin excretion rate; Ethnic differences **39**, 93

Metformin; Cardiovascular disease; Insulin resistance; Weight reduction **39**, 47

Microalbuminuria; Type-2 diabetes; Metabolic control; Hypertension **39**, 39

Minimal model; Insulin sensitivity; Glucose effectiveness; Interstitial insulin; Obesity **39**, 129

Mitochondrial gene; Hypoglycemia; Myocardial ischemia; IDDM **39**, 31

Mortality; Aged; Diabetes; Follow-up study; Glucose tolerance; Prognosis **39**, 75

Myocardial ischemia; Hypoglycemia; IDDM; Mitochondrial gene **39**, 31

Necrotising-fascitis; Diabetes mellitus; Infection; Malignant otitis externa; Psoas abscess; Fournier's gangrene **39**, 123

Nephropathy; Non-insulin dependent diabetes mellitus; Retinopathy; Neuropathy; Prevalence **39**, 185

Nephropathy; Prevalence; Diabetes; Retinopathy; Loss of pallesthesia macrovascular complications **39**, 157

Nephropathy; Proliferative retinopathy; Type 1 diabetes **39**, 11

Neuropathy; Non-insulin dependent diabetes mellitus; Retinopathy; Nephropathy; Prevalence **39**, 185

Neuropathy screening instrument; Diabetic neuropathy; Diabetic neuropathy score; Diabetes mellitus **39**, 165

NIDDM; Blood pressure; CHD; BMI; WHR; Relative risk **39**, 147

NIDDM; Cardiovascular morbidity; Proteinuria; Hypertension **39**, 63

NIDDM; Skin lesions; Diabetes mellitus; IDDM; Metabolic control **39**, 101

Non-insulin-dependent diabetes mellitus; Apolipoprotein AI-containing particles; Atherosclerotic risk; Electroimmunoassay; High density lipoprotein subfractions **39**, 201

Non-insulin-dependent diabetes mellitus; Elevated urinary albumin excretion rate; Metabolic syndrome; Ethnic differences **39**, 93

Non-insulin dependent diabetes mellitus; Retinopathy; Nephropathy; Neuropathy; Prevalence **39**, 185

Non-insulin mediated glucose uptake; Diabetes mellitus; Obesity; Acromegaly; Cushing's disease **39**, 107

Obesity; Minimal model; Insulin sensitivity; Glucose effectiveness; Interstitial insulin **39**, 129

Obesity; Non-insulin mediated glucose uptake; Diabetes mellitus; Acromegaly; Cushing's disease **39**, 107

Painful peripheral neuropathy; Diabetes mellitus; Acupuncture **39**, 115

Pathogenesis; *Helicobacter pylori* seroprevalence; Diabetes mellitus **39**, 143

Personality; Type 1 (insulin–dependent) diabetes mellitus; Insulin; Treatment satisfaction; Basal-bolus insulin regimen **39**, 23

Prevalence; Diabetes; Retinopathy; Nephropathy; Loss of pallesthesia macrovascular complications **39**, 157

Prevalence; Non-insulin dependent diabetes mellitus; Retinopathy; Nephropathy; Neuropathy **39**, 185

Prognosis; Aged; Diabetes; Follow-up study; Glucose tolerance; Mortality **39**, 75

Proliferative retinopathy; Nephropathy; Type 1 diabetes **39**, 11

Proteinuria; Cardiovascular morbidity; NIDDM; Hypertension **39**, 63

Psoas abscess; Diabetes mellitus; Infection; Malignant otitis externa; Necrotising-fascitis; Fournier's gangrene **39**, 123

Quantification; Autoantibodies; IDDM; RIA; Colloidal gold; Human pancreas **39**, 173

Relative risk; Blood pressure; CHD; NIDDM; BMI; WHR **39**, 147

Renal transplantation; Diabetic neuropathy; Diabetic nephropathy; Diabetes mellitus **39**, 55

Retinopathy; Non-insulin dependent diabetes mellitus; Nephropathy; Neuropathy; Prevalence **39**, 185

Retinopathy; Prevalence; Diabetes; Nephropathy; Loss of pallesthesia macrovascular complications **39**, 157

RIA; Autoantibodies; IDDM; Colloidal gold; Quantification; Human pancreas **39**, 173

Skin lesions; Diabetes mellitus; IDDM; NIDDM; Metabolic control **39**, 101

Spontaneously hypertensive rat; Adenosine analogue; Hyperglycemia; Glucose; Free fatty acid; Triglyceride **39**, 3

Sulfonylurea; Type 2 diabetes mellitus; Insulin **39**, 193

Treatment satisfaction; Type 1 (insulin–dependent) diabetes mellitus; Insulin; Personality; Basal-bolus insulin regimen **39**, 23

Triglyceride; Adenosine analogue; Spontaneously hypertensive rat; Hyperglycemia; Glucose; Free fatty acid **39**, 3

Type 2 diabetes mellitus; Sulfonylurea; Insulin **39**, 193

Type-2 diabetes; Metabolic control; Microalbuminuria; Hypertension **39**, 39

Type 1 diabetes; Proliferative retinopathy; Nephropathy **39**, 11

Type 1 (insulin–dependent) diabetes mellitus; Insulin; Personality; Treatment satisfaction; Basal-bolus insulin regimen **39**, 23

Weight reduction; Metformin; Cardiovascular disease; Insulin resistance **39**, 47

WHR; Blood pressure; CHD; NIDDM; BMI; Relative risk **39**, 147